Cadrenal Net Income from 2010 to 2025
| CVKD Stock | 19.03 0.49 2.64% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -7.5 M | Current Value -7.9 M | Quarterly Volatility 511.5 K |
Check Cadrenal Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cadrenal Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 K, Interest Expense of 14.6 K or Other Operating Expenses of 5.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.18. Cadrenal financial statements analysis is a perfect complement when working with Cadrenal Therapeutics, Valuation or Volatility modules.
Cadrenal |
Latest Cadrenal Therapeutics,'s Net Income Growth Pattern
Below is the plot of the Net Income of Cadrenal Therapeutics, Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cadrenal Therapeutics, financial statement analysis. It represents the amount of money remaining after all of Cadrenal Therapeutics, Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cadrenal Therapeutics,'s Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cadrenal Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.36 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cadrenal Net Income Regression Statistics
| Arithmetic Mean | (6,941,387) | |
| Geometric Mean | 6,925,156 | |
| Coefficient Of Variation | (7.37) | |
| Mean Deviation | 368,969 | |
| Median | (6,714,329) | |
| Standard Deviation | 511,525 | |
| Sample Variance | 261.7B | |
| Range | 1.6M | |
| R-Value | (0.63) | |
| Mean Square Error | 167.7B | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | (68,101) | |
| Total Sum of Squares | 3.9T |
Cadrenal Net Income History
Other Fundumenentals of Cadrenal Therapeutics,
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
About Cadrenal Therapeutics, Financial Statements
Cadrenal Therapeutics, stakeholders use historical fundamental indicators, such as Cadrenal Therapeutics,'s Net Income, to determine how well the company is positioned to perform in the future. Although Cadrenal Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cadrenal Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Cadrenal Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cadrenal Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cadrenal Therapeutics, is a strong investment it is important to analyze Cadrenal Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cadrenal Therapeutics,'s future performance. For an informed investment choice regarding Cadrenal Stock, refer to the following important reports:Check out the analysis of Cadrenal Therapeutics, Correlation against competitors. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.